Xeris Biopharma Holdings (XERS) shares surged 29% in Thursday trading after the company reported Q3 results that topped Wall Street estimates.
In the three months ended Sept. 30, earnings were $0.06 per diluted share, compared with breakeven a year earlier.
Three analysts polled by FactSet expected $0.02.
Revenue rose to $107.2 million from $74.4 million a year earlier.
Analysts projected $101.7 million.
Xeris raised its 2026 revenue outlook to $395 million to $405 million from the previous range of $385 million to $390 million. Analysts expect $387.9 million.
Price: 13.53, Change: +3.07, Percent Change: +29.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments